Premaitha Health is pleased to announce significant commercial progress in the Middle East through its distribution network.
Premaitha has appointed distributors across the Middle East and these partners have signed a number of new Middle Eastern customers which in aggregate are expected to generate over 10,000 samples per annum, once fully operational. The region offers greater intellectual property freedom, is attracted to the high quality in vitro diagnostic solution offered by Premaitha and is rapidly adopting non-invasive prenatal testing (“NIPT”) as a general screening test.
Dr Stephen Little, CEO of Premaitha Health, commented: “We are pleased to report increasing traction in the Middle East, where our existing installations are exceeding expectations and where we are seeing strong demand in local hospitals through our distributor network. This is a strategically important region which is unaffected by ongoing intellectual property disputes and therefore further de-risks the Company’s position in this regard.
“It is clear that there is increasing recognition of the benefits of NIPT as a general screening test in the region and this in turn is driving demand for the IONA® test as a complete in-house solution. The financial impact from these contracts will build during our next financial year creating a strong platform for recurring revenues in the years ahead. The Middle East is positioning itself as a leading global healthcare destination and we are rapidly establishing a significant market presence in the region.”
See the announcement in full here